Wetherby probiotics developer agrees five-year Mexican deal

Steen Andersen, Probiotix
Biotech innovator ProBiotix Health has agreed a five-year commercial partnership allowing a Mexican company exclusive use of one of its patented products. LPLDL® is a naturally-occurring probiotic which has been proven to have a positive impact on HDL cholesterol and blood pressure, among other things. The deal will see Mexico-based Raff use LPLDL® as an ingredient for the local manufacturing of finished products. The launch is planned for the first half of 2025, with commercial sales expected in late 2025/early 2026. It also ... You can carry on reading TheBusinessDesk.com for free, but you have reached the maximum number of pages an unregistered user can view. To register for an account, click here or login below...
Close